The enzyme carnitine palmitoyltransferase I (CPT I) 1 plays a major role in the regulation of mitochondrial ␤-oxidation in all mammalian tissues. CPT I catalyzes the first step in the transport of long-chain acyl groups from the cytosol into the mitochondrial matrix, where they undergo ␤-oxidation. Inhibition by malonyl-CoA is a major regulatory property of CPT I and confers to the enzyme the ability to signal to the cell the relative availability of carbohydrate and lipid fuels (see Ref. 1 for recent review). Therefore, the enzyme plays a central role in the control of hepatic, cardiac, and skeletal muscle and pancreatic ␤-cell function and is a potential pharmacological target for the treatment of metabolic disorders ranging from diabetes to insulin resistance and coronary heart disease (2) (3) (4) (5) In mammals, CPT I exists as two distinct isoforms that are the products of different genes: the liver (L) type or ␣ form and the muscle (M) type or ␤ form (6, 7) . When assayed in isolated mitochondria, these two CPT I variants differ markedly in key kinetic characteristics in that M-CPT I has a much lower IC 50 for malonyl-CoA and a higher K m for L-carnitine than L-CPT I (8, 9) . However, their affinity for long-chain acyl-CoA is not markedly different (9) . They also differ in their responses to altered physiological states (the malonyl-CoA sensitivity and K m for palmitoyl-CoA are altered only for L-CPT I (10)) and incubation conditions of isolated mitochondria (L-CPT I shows pronounced hysteretic behavior with respect to malonyl-CoA, whereas M-CPT I does not (11) ).
CPT I is an integral membrane protein that has two transmembrane segments (TM1 and TM2) within the N-terminal 15% of its primary sequence (see Figs. 1 and 2) (12) . In the mitochondrial outer membrane, it adopts a polytopic orientation such that both the N-and C-terminal (catalytic) domains, composed of ϳ46 and 651 residues, respectively, are exposed on the outer (cytosolic) surface of the membrane (12) (13) (14) . A short loop of 27 amino acid residues connects the two transmembrane segments and protrudes into the intermembrane space between the outer and inner membranes of the mitochondrion (12) . Previous results demonstrated that N/C-terminal domain interactions are important in determining the kinetic characteristics of L-CPT I (12, 14) . Proteolytic cleavage of the extreme N terminus causes total loss of the malonyl-CoA sensitivity of the enzyme and partial loss of its catalytic activity (12) . In addition, interactions of regions of the molecule with the membrane have been suggested to explain the marked dependence of the kinetic properties of the enzyme (particularly its malonyl-CoA sensitivity) on the molecular order of the membrane lipids both in vivo (15) and in vitro (16) . Functional mutagenesis studies have confirmed that the N-terminal 18 amino acid residues (and particularly Glu-3) of the L-CPT I protein are required for malonyl-CoA sensitivity (17, 18) , a parameter that is also affected by mutation of His-5 and, on the C-terminal domain, of His-140 (19) . Deletion of the N-terminal 30 amino acid residues of M-CPT I also largely abolishes its malonyl-CoA sensitivity (20) .
This study was undertaken systematically to investigate the roles of the different domains of the molecule in substrate and inhibitor interactions and to exploit the availability of isoforms (L-and M-type) that have distinct kinetic parameters. These isoforms are closely related in amino acid sequence, having an overall 62% sequence identity, with regions, including the cytosolic N-terminal sequence, of much higher similarity. They are therefore presumed to have the same overall structure (see Fig. 1 ). By determining the kinetic parameters of chimeras constructed from different domains of L-and M-CPT I isoforms, it was reasoned that it would be possible to elucidate the roles of different regions of the molecule in determining the distinctive properties of the two isoforms. Studies on other transmembrane proteins have shown that it is highly energetically favorable to have physical interaction between transmembrane helices (see Ref. 21) . Thus, our chimeras were designed to perturb the native interactions between TM1 and TM2 and/or the putative interactions between the N-and C-terminal domains.
For the purpose of these studies, the molecule was divided into three discrete regions: the N-terminal domain plus TM1, the loop plus TM2, and the C-terminal domain (see Fig. 1 ). Thus, six chimeras were constructed and expressed in Pichia pastoris, which has previously been shown to be a good expression system for CPT I (22, 23) . The use of an expression background free from endogenous CPT activity allowed detailed kinetic analyses to be performed. The kinetic parameters for the substrates carnitine and palmitoyl-CoA and the inhibitor malonyl-CoA were examined for the chimeric CPT I molecules and the two expressed parental enzymes. Our results reveal a more complex set of intramolecular interactions than has hitherto been reported (19) . The kinetic characteristics of chimeric proteins containing the C-terminal domain of L-CPT I are dependent on the precise pairings between the respective Nand C-terminal domains and between TM1 and TM2, but the C-terminal domain of M-CPT I is much less sensitive to alterations in these interactions. The results are discussed in relation to the differences in responses of the two isoforms to altered conditions both in vivo and in vitro.
EXPERIMENTAL PROCEDURES
Materials-These were obtained as described previously (23) , except where stated.
Construction of Expression Plasmids-Full-length cDNAs for the rat L-CPT I (LLL) and M-CPT I (MMM) isoforms were obtained by screening a rat skeletal muscle cDNA library (Stratagene no. 937510). Probes corresponding to nucleotides 82-534 (GenBank TM /EBI accession number L07736) of L-CPT I and nucleotides 21-512 of M-CPT I (accession number D43623) were generated by PCR from rat heart cDNA using oligonucleotides AGCAATAGGTCCCCACTCAA and GCTCATTTTGC-CGTGTTCTG and oligonucleotides CCCAGGATGGCGGAAGCACACC and CCGGCTGGACAGGAGACGAACAC, respectively. Library screening was performed as described previously (23) . The cDNAs were excised from the libraries into pBluescript SK(Ϫ), and the sequences of the coding regions were verified to be identical to those already published.
To generate the chimeras LLM and MML (see Fig. 2A ), a silent AflII restriction site (CTTAAG corresponding to amino acids Leu-Lys; residues 126 and 127 and residues 128 and 129 of the L-and M-type isoforms, respectively) was introduced into the cDNAs for both isoforms (shown in italics in the oligonucleotides below). This single nucleotide change was introduced by overlap extension PCR. For L-CPT I, two independent PCRs (20 cycles each) were performed with primers A (TTGCGGCCGCAATAGGTCCCCACT) and B (GCAGCACCTTAAGC-GAGTAGCG) and primers C (GCTACTCGCTTAAGGTGCTGC) and D (TCCTCGAGGCCTTACAGATTCCAG) using the rat L-CPT I cDNA as template. The two products were annealed and reamplified for a further five cycles of PCR using primers A and D. The same method was used for rat M-CPT I using TTGCGGCCGCAGGATGGCGGAAGCACAC-CAGGCAGTA (primer E), GCAGCAGCTTAAGGGTTTGTCGGACCG-ACAAACCCTTAAGCTGCTGC, and primer F (GGTCTAGACAAGGG-CCGCACAGAATCCA). In each case, a novel NotI site (shown in italics) was also introduced upstream of each of the respective start codons. All PCRs were performed using Pfu TURBO DNA polymerase (Stratagene).
The LLL cDNA was subcloned into pGAPZ B using the NotI site from pBluescript and the naturally occurring EcoRI site in the 3Ј-untranslated region. The PCR product (containing the AflII site) was used to replace the 5Ј-ends of the cDNAs upstream of the unique KpnI site. The MMM cDNA was subcloned into pcDNA3.1 at the NotI-XhoI sites, using sites from the pBluescript vector. The 5Ј-end (NotI-HindIII) was then replaced with the PCR product, and the whole cDNA was transferred to pGAPZ B using NotI and the XbaI site from the pcDNA vector.
The sequence ATTTTTTTATTC (encoding amino acids 121-124, IFLF) in the M-CPT I cDNA, which resembles a known yeast polyadenylation signal, was subsequently changed to ATCTTCCTCTTC in an attempt to increase expression levels without changing the amino acid sequence. A cleaved PCR product (primer E, above, and AGCT-TAAGAGTTTGTCGGAAGAGGAAGATGCCTGTCGCCCAG) was used to replace the NotI-AflII fragment.
The chimeras LLM and MML (see Fig. 2A ) were generated from LLL and MMM by swapping the NotI-AflII restriction fragments. The chimeras LMM and MLL were generated individually. Briefly, LMM was made by replacing the SphI-AflII fragment of LLM (corresponding to the loop and TM2) with a PCR product generated from the corresponding region of M-CPT I (with the polyadenylation site removed), except that a 5Ј-SphI site was added and a single amino acid change (Val to Ile) was introduced into the loop (PCR primers ATGCATGCTAAAATC-GATATCAGTATGGGGCTGGTCC and F above) (see Fig. 2A ). MLL was made by replacing the NcoI-AflII region in MML with a PCR product generated from the corresponding region of L-CPT I with an added 5Ј-NcoI site (PCR primers TTCCTCCATGGGCATGATCGCAAAGAT and D above). LML and MLM were subsequently generated from LMM and MLL by swapping NotI-AflII restriction fragments. All the mutations and junctions were verified by sequencing.
Transformation and Expression in P. pastoris-P. pastoris strain X-33 was used throughout these studies. All procedures were performed as recommended by the expression system distributor, Invitrogen (San Diego, CA). Expression was driven by the constitutive glyceraldehyde-3-phosphate dehydrogenase promoter (24) using the vector pGAPZ. High copy number clones were selected where necessary using 0.5 or 1 mg/ml Zeocin. Cultures for activity measurements were grown for 24 h in YPD medium (1% yeast extract, 2% peptone, 2% glucose), and cellfree extracts were prepared as described previously (23) .
CPT Assay-CPT I activity was measured at different carnitine, palmitoyl-CoA, and malonyl-CoA concentrations, as indicated, as described previously (23) . Assays were performed on cell-free yeast extracts rather than mitochondrion-enriched fractions for reasons discussed previously (23) . It was shown that for both L-and M-CPT I, identical kinetic behavior was observed in the two fractions (23) . When concentrations of carnitine were varied, that of palmitoyl-CoA was fixed at 135 M. When concentrations of palmitoyl-CoA were varied, that of carnitine was fixed at 500 M. For malonyl-CoA inhibition studies, palmitoyl-CoA and carnitine concentrations were fixed at 35 and 500 M, respectively.
Presentation of Data and Statistical Analysis-Data were fitted to the Michaelis-Menten equation for palmitoyl-CoA and carnitine or to the equation for simple competitive inhibition in the case of malonylCoA. Curve fitting was performed using Sigma-Plot software with nonlinear regression analysis as described previously (23) .
For each of the three parameters (malonyl-CoA, palmitoyl-CoA, and carnitine) and for each catalytic domain (L-or M-type), separate general linear models were used to examine the effects of the identity (L-or M-type) of the remaining two regions of the chimeric molecules. Where the two-way statistical interaction between the two regions was significant, Tukey's post-hoc multiple comparisons test was used to examine the differences between the four mean values. In general, it was found that residuals in the various models when applied to the raw data increased with the mean, and so the values were log-transformed prior to analysis. Since the data were unbalanced, to ensure that p values were genuine, sequential sums of squares in the general linear model were also investigated with the order of the factors reversed, and in addition, the results were checked using the residual maximum likelihood method (REML). Minitab software (Version 12) was used to apply the general linear models, and Genstat 5 was used for REML.
RESULTS

Expression of Wild-type Rat L-and M-CPT I
This study describes the first heterologous expression of rat M-CPT I in P. pastoris. In preliminary experiments, only very low levels of M-CPT I activity could be detected, even when selection for high copy number genomic integration events with high Zeocin concentrations was used. This was presumed to be due to premature termination of transcripts in AT-rich regions and has been observed in Pichia and other eukaryotic systems. In particular, the sequence TTTTTATA is known to promote premature polyadenylation in Saccharomyces cerevisiae, and a similar sequence has been shown to cause termination when the human immunodeficiency virus type 1 gp120 protein is expressed in P. pastoris (25) . When the sequence TTTTTATTC present in rat M-CPT I (encoding amino acids 122-124) was mutated (without changing the amino acid sequence; see "Experimental Procedures"), higher levels of expressed activity were achieved, although it was still necessary to select for high copy number integrants. It is noteworthy that in human M-CPT I, the corresponding sequence is TTCTTCTTC, and the protein was readily expressed from the glyceraldehyde-3-phosphate dehydrogenase promoter from single copy clones (22) . For rat L-CPT I, good levels of CPT activity were achieved when present at single copy within the Pichia genome (after selecting for transformants with 0.1 mg/ml Zeocin).
Expression and Kinetic Characterization of Chimeric CPT I Constructs
For the purpose of these studies, the molecule was divided into three discrete regions (Fig. 1 ) based on the primary amino acid sequence (Fig. 2) : the N-terminal domain plus TM1, the loop plus TM2, and the C-terminal domain (residues 1-82, 83-126, and 127-772, respectively, in L-CPT I). Due to the low degree of sequence conservation observed in the loop of CPT I isoforms from different mammalian species and the low degree of functional importance inferred from the topology of the protein, this region was not considered separately, but in conjunction with TM2. The N-terminal domain shows a very high degree of sequence conservation between the L-and M-type isoforms ( Fig. 2A) . In particular, the first 18 residues in L-and M-CPT I are identical in all known mammalian CPT I sequences. Therefore, the N-terminal domain was not addressed separately, but in combination with TM1. Using all combinations of the three regions allowed generation of six chimeras, plus the two parental molecules. No amino acids were omitted Fig. 2A) is in the loop region and is also a substitution that occurs between rat or mouse and human in L-CPT I. The chimeras are referred to using a threeletter nomenclature as shown in Fig. 2A . Thus, LLL and MMM refer to the two parental proteins.
For chimeras containing the L-type catalytic domain, high levels of CPT activity were expressed from single copy clones. For chimeras containing the M-type C-terminal domain, high copy number integrants had to be used to achieve readily measurable activity levels, as was the case for the parental M-CPT I (MMM). In the constructs MML, LML, and LMM, the T-rich nucleotide sequence was altered as described above for MMM. All the kinetic characteristics of the expressed chimeras are given in Table I , but in the interests of clarity, they are considered separately, below, for those containing the L-or M-type catalytic domain.
Kinetic Properties of Chimeras with the L-type Catalytic Domain (MLL, LML, and MML)
Velocity versus substrate/inhibitor concentration curves for palmitoyl-CoA, carnitine, and malonyl-CoA are given in Fig. 3 . For both carnitine and palmitoyl-CoA, the data obeyed standard Michaelis-Menten kinetics, thus enabling the accurate calculation of K m values by graphical methods. The assay conditions were designed (26) to give high values for the IC 50 for malonyl-CoA (concentration required to inhibit CPT I activity by 50%). This enabled the more accurate determination of IC 50 values, thus allowing the detection of subtle changes in this parameter.
Malonyl-CoA Inhibition-The IC 50 for malonyl-CoA was the same for LLL and LML (38.4 Ϯ 2.24 and 35.1 Ϯ 4.1 M, respectively), suggesting that TM1/TM2 interactions do not affect malonyl-CoA sensitivity as long as the N/C-terminal domain interactions (LxL) present in the parental form are maintained. By contrast, the chimeric enzymes MML and MLL both had IC 50 values for malonyl-CoA that were Ͼ1.5-fold higher than those of the parental control ( Table I ), indicating that disruption of the N/C-terminal domain interactions negatively affects malonyl-CoA action.
K m for Palmitoyl-CoA-The same pattern of changes was observed for the affinity for palmitoyl-CoA as that observed above for malonyl-CoA (Table I) . Thus, LLL and LML had very similar K m values (46.0 Ϯ 5.1 and 36.9 Ϯ 7.2 M, respectively; not significantly different), whereas those for MML and MLL (63.9 Ϯ 6.6 and 64.7 Ϯ 6.5 M, respectively) were both 1.5-fold higher (p Ͻ 0.01) than the value for the parental protein. Therefore, in chimeric CPT I proteins with the L-type catalytic domain, the effects of malonyl-CoA and palmitoyl-CoA on activity appear to be modulated by alterations in N/C-terminal domain interactions, whereas changes in TM1/TM2 interactions do not affect either parameter. 
Kinetic Properties of Chimeras Containing the M-type Catalytic Domain (LMM, MLM, and LLM)
IC 50 for Malonyl-CoA-The IC 50 for malonyl-CoA of the parental enzyme MMM was 10-fold lower (3.3 Ϯ 0.2 M) than that of the parental L-CPT I (LLL). All the chimeras containing the M-type catalytic domain had very similar IC 50 values ( Table I) , suggesting that the degree of malonyl-CoA sensitivity of the C-terminal domain of M-CPT I is determined solely by the structural characteristics within that domain and is not dependent on the identity of the rest of the molecule.
K m for Palmitoyl-CoA-As expected from previous studies on liver and muscle mitochondria, the K m for palmitoyl-CoA of M-CPT I (MMM; 57.4 Ϯ 5.5 M) was similar to that of L-CPT I (LLL; 46.0 Ϯ 5.1 M). The affinity for palmitoyl-CoA was not affected (Table I) K m for Carnitine-The K m for carnitine of M-CPT I (MMM; 780 Ϯ 80 M) was 4-fold higher than that of LLL, as expected from the relative affinities for this substrate shown by the respective enzymes in isolated rat muscle and liver mitochondria (9) . Substitution of the N-terminal domain and TM1 (in LMM) significantly (p ϭ 0.02) lowered the K m by 20% (to 612 Ϯ 10 M). This effect was reversed in LLM, i.e. when TM2 was also substituted. Substitution of TM2 only (by liver-type TM2, in MLM) resulted in an even bigger (2-fold) increase in K m for carnitine to 1.3 Ϯ 0.2 mM. These observations indicate that the higher K m of M-CPT I is not solely determined by the characteristics of the C-terminal domain. Indeed, the M-type catalytic domain showed a wide range of values for K m for carnitine across the chimeric constructs (Table I and Fig. 4) , with the lowest value resulting from substituting the N-terminal domain and TM1 region and the highest value resulting from substituting TM2.
DISCUSSION
Using the Pichia expression system, we were able to determine accurate kinetic parameters for L-and M-CPT I and the six chimeric derivatives. In particular, the lack of sigmoidicity for the CPT activity versus substrate concentration curves allowed fitting of the data to the standard Michaelis-Menten equation. The kinetics of M-and L-CPT I differ most strikingly with respect to the IC 50 for malonyl-CoA and the K m for carnitine when measured in muscle and liver mitochondria (8, 9) . These differences were fully preserved in the proteins expressed from the respective parental constructs in P. pastoris.
The primary amino acid sequence of the 46-residue cytosolic N-terminal domain of CPT I is identical or highly conserved in the L-and M-type isoforms, with three semiconservative differences (Fig. 2B) . However, there is a notable difference between sequences of their transmembrane segments. M-CPT I has a basic residue (Arg-52) within the hydrophobic stretch of TM1 (Fig. 2B) . This L/M-CPT I difference is conserved in all known mammalian CPT I sequences. This may make this TM region shorter than that in L-CPT I and extend the cytosolic N-terminal domain accordingly. Alternatively, this charged residue might restrict the mobility of the transmembrane (presumed) helix within the membrane environment, contributing toward an overall more rigid structure for M-CPT I. These possibilities are currently being investigated.
We have previously suggested that interaction between the N-terminal region and the catalytic C-terminal domain of L-CPT I is important in determining malonyl-CoA sensitivity (14) . Similarly, we have emphasized that it is highly likely that TM1 and TM2 interact strongly with each other as well as with annular membrane lipids of the protein (21) . These predictions have now been tested. From the data, we conclude that the precise nature of these interactions is important in determining the kinetics of the L-CPT I catalytic domain. This is contrary to previous conclusions by Swanson et al. (19) derived from analysis of two rat CPT I chimeras expressed in a mammalian cell line. The reason for this discrepancy is not immediately apparent, as the chimera involving the L-type C-terminal domain studied by those authors was similar to our MLL, which shows a Ͼ2-fold increase in K m for carnitine (Table I) . Moreover, in the aforementioned study, no measurements of the K m for palmitoyl-CoA were performed, presumably because of the high background activity of endogenous CPT I and CPT II in COS cells (19) . It was also concluded that the IC 50 for malonyl-CoA was not affected by N/C-terminal domain interactions for either M-or L-CPT I. Although this is true for the M-type catalytic domain, it is evidently not so for the L-type catalytic domain (Table I) . A chimera similar to our MLL (using rat L-and human M-CPT I (20)) was also found to have a higher IC 50 for malonyl-CoA. However, the simultaneous disruption of N/C-terminal domain and TM1/TM2 interactions in that chimera, coupled with the absence of other relevant chimeras, allowed no definite conclusions to be drawn by those authors about the relative importance of the different types of intramolecular interactions for the L-type catalytic domain. The effect of similar disruptions on the M-type catalytic domain was not addressed in their study. Our study thus benefits from the ability both to determine accurate kinetics in the absence of endogenous CPT activity and to resolve the effects of different intramolecular interactions through the use of several chimeras. Any potential for intermolecular interaction between the endogenous CPT I molecules and those expressed experimentally was also eliminated in our studies.
A striking observation of this study is that the kinetics with respect to palmitoyl-CoA and to carnitine respond to changes in different characteristics of the chimeras. Affinity for palmitoylCoA was mostly responsive to altered N/C-terminal domain interactions, especially for the L-type catalytic domain. By contrast, the K m for carnitine was mostly responsive to TM1/ TM2 interactions and especially for the M-type catalytic do- Table I. main. As shown in Fig. 4 , these interactions mean that a continuous range of K m values for carnitine can be obtained for proteins expressed from different combinations of the three regions of L-or M-CPT I from which the six chimeras were constructed.
In rat liver mitochondria, alterations in membrane lipid order affect the kinetic parameters of L-CPT I for malonyl-CoA and palmitoyl-CoA (15, 16) . This might arise through altered N/C-terminal domain interactions or, directly or indirectly, through altered inter-TM interactions. The present data suggest that the latter is not the case. Indeed, it was the K m for carnitine that was altered by perturbation of TM interactions, and not the kinetic parameters for palmitoyl-CoA or malonylCoA (see above). Importantly, this effect on the K m for carnitine was observed for both the L-and M-type series of constructs (Fig. 4 and Table I ), suggesting that the kinetics of carnitine binding to either isoform is dependent on TM1/TM2 interactions. To our knowledge, effects of membrane lipid order on carnitine kinetics have not been examined; however, our results predict that this parameter would not be greatly influenced by changes in membrane lipid composition that occur in vivo (15) . Our data show that the kinetics for carnitine, on the one hand, and for malonyl-CoA and palmitoyl-CoA, on the other, appear to be affected independently. This suggests that the inverse relationship between the values of these two parameters for CPT I assayed in mitochondria from different tissues (9) does not result from an obligatory link between the respective binding sites. Indeed, whereas a continuous range of affinities for carnitine can be produced by altering the combinations of L-and M-CPT I domains used in the constructs (Fig.  4) , IC 50 values for malonyl-CoA fall into two discrete groups, depending on the identity of the catalytic domain (Table I ; cf. Ref. 19) , although the value for the L-type catalytic domain is capable of modulation by the structure of the rest of the molecule (Table I) .
The difference between the C-terminal domains of the two CPT I isoforms in their dependence on N/C-terminal domain and TM1/TM2 interactions may not only reflect the major differences in kinetics between them (see Introduction), but may also account for the differences in their respective responses to conditions that alter membrane lipid molecular order in vivo (15) and in isolated mitochondria in vitro (11, 16) . It may also explain why the activity and malonyl-CoA sensitivity of the M-type catalytic domain are more resistant to N-terminal truncations (17, 20) . Importantly, the changes in kinetic parameters observed for L-CPT I upon mismatching of N-and C-terminal domains or TM1/TM2 pairings were of the same magnitude as those observed under the same assay conditions for L-CPT I in liver mitochondria isolated from rats in different metabolic states (26 -28) . Thus, in liver mitochondria isolated from fasted rats, the IC 50 for malonyl-CoA and K m for palmitoyl-CoA of L-CPT I are both 2-4-fold higher than those in mitochondria from fed animals (28) . This suggests that conformational changes of the same order are established within L-CPT I when induced either by altered membrane composition in vivo or through changes in intramolecular interactions produced in our chimeras.
In chimeras containing the L-type C-terminal domain, the effects of palmitoyl-CoA and malonyl-CoA were altered by substitution of the N terminus and TM1 (in MxL). As discussed above, the most obvious differences between L-and M-type amino acid sequences for this region are in TM1 rather than in the cytosolic N terminus. It is suggested that conformational changes that affect the positioning (laterally or transversely) of TM1 relative to the membrane (but independent of the identity of TM2) are important in determining the way that the cytosolic N-terminal domain emerges from the membrane and interacts with the C-terminal domain. It is possible that it is solely the arginine residue in muscle-type TM1 that accounts for the differences between LxL and MxL, namely the raised IC 50 and K m for palmitoyl-CoA for the latter. Studies are being conducted to explore this possibility and to investigate the role of the other conservative/semiconservative differences between the amino acid sequences of the respective N-terminal domains.
The fact that the malonyl-CoA sensitivity of the M-CPT I catalytic domain is much less influenced by changes in either N/C-terminal domain or TM1/TM2 interactions and, by implication, by any changes in these interactions brought about by altered membrane fluidity in vivo explains the previous observations that the kinetics of this isoform in heart and muscle do not change under different physiological conditions (10) . Similarly, it is interesting that, unlike L-CPT I, heart mitochondrial CPT I does not show any hysteretic behavior with respect to malonyl-CoA in vitro (11) . Coupled with the fact that the IC 50 for malonyl-CoA of M-CPT I is already Ͼ10-fold lower than that of L-CPT I, these observations suggest that the catalytic domain of M-CPT I adopts a much more rigid conformation that maintains its structure in a highly malonyl-CoA-sensitive state independently of changes in N/C-terminal domain and TM1/ TM2 interactions mediated by changes in membrane lipid molecular order. However, as is the case for L-CPT I (1, 12, 14, 17) , the presence of an intact cytosolic N terminus is still required for malonyl-CoA sensitivity of M-CPT I (20) .
Structural data for CPT I are not yet available in view of its nature as an integral membrane protein. In their absence, studies such as those presented here are invaluable for furthering our understanding of structure/function relationships within the molecule. Our studies extend the understanding of the complexity of the intramolecular interactions of CPT I as it relates to the distinct kinetics of the two isoforms. In particular, our studies provide insights into the molecular mechanisms underlying their different hysteretic behavior with respect to the inhibitor malonyl-CoA and the response to altered physiological state previously observed for the liver-and muscle-type CPT I isoforms. Indeed, especially in the case of the liver-type isoform, any future understanding derived from the determination of its static structure will need to be supplemented by studies addressing conformational changes within the molecule induced by intramolecular interactions.
